We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sage Therapeutics Inc | NASDAQ:SAGE | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.15 | -1.87% | 7.86 | 7.70 | 8.72 | 8.03 | 7.70 | 8.01 | 633,422 | 23:55:34 |
From Aug 2022 to Aug 2024
By Colin Kellaher
Biogen Inc. and Sage Therapeutics Inc. on Monday said the U.S. Food and Drug Administration granted priority review to the application seeking approval of zuranolone for the treatment of major depressive disorder and postpartum depression.
The Cambridge, Mass., companies said the agency set a target action date of Aug. 5 for the application.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
Sage and Biogen said zuranolone, a 14-day, fast-acting oral treatment, has the potential to provide a meaningful new option to help address the significant unmet medical need in depression.
The companies in 2020 inked a global collaboration and license agreement to jointly develop and commercialize zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 06, 2023 07:03 ET (12:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sage Therapeutics Chart |
1 Month Sage Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
